Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Parsaclisib by Incyte for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Parsaclisib is under clinical development by Incyte and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to...
Data Insights
Parsaclisib by Incyte for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Parsaclisib is under clinical development by Incyte and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According to...